CN105246500A - 基质金属蛋白酶及其用途 - Google Patents

基质金属蛋白酶及其用途 Download PDF

Info

Publication number
CN105246500A
CN105246500A CN201480030453.7A CN201480030453A CN105246500A CN 105246500 A CN105246500 A CN 105246500A CN 201480030453 A CN201480030453 A CN 201480030453A CN 105246500 A CN105246500 A CN 105246500A
Authority
CN
China
Prior art keywords
mmp
tissue
mmps
prommp
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480030453.7A
Other languages
English (en)
Chinese (zh)
Inventor
克劳迪娅·齐尔贝尔博格
格雷格·B·菲尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN105246500A publication Critical patent/CN105246500A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24017—Stromelysin 1 (3.4.24.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24024—Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24034—Neutrophil collagenase (3.4.24.34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
CN201480030453.7A 2013-04-05 2014-04-04 基质金属蛋白酶及其用途 Pending CN105246500A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808861P 2013-04-05 2013-04-05
US61/808,861 2013-04-05
PCT/US2014/033009 WO2014165780A2 (en) 2013-04-05 2014-04-04 Matrix metalloproteinases and uses thereof

Publications (1)

Publication Number Publication Date
CN105246500A true CN105246500A (zh) 2016-01-13

Family

ID=51659357

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480030453.7A Pending CN105246500A (zh) 2013-04-05 2014-04-04 基质金属蛋白酶及其用途

Country Status (15)

Country Link
US (1) US20160053250A1 (https=)
EP (2) EP2981276A4 (https=)
JP (1) JP2016520550A (https=)
KR (1) KR20160006694A (https=)
CN (1) CN105246500A (https=)
AU (1) AU2014248002A1 (https=)
BR (1) BR112015025390A2 (https=)
CA (1) CA2908739A1 (https=)
CR (1) CR20150603A (https=)
HK (1) HK1221405A1 (https=)
MX (1) MX2015014053A (https=)
PH (1) PH12015502306A1 (https=)
RU (1) RU2015147878A (https=)
SG (1) SG11201508199QA (https=)
WO (1) WO2014165780A2 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105412917A (zh) * 2014-09-19 2016-03-23 达森生物药业有限公司 治疗实体瘤的抗癌组合物及其用途
CN105412916A (zh) * 2014-09-19 2016-03-23 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
CN105477628A (zh) * 2014-09-19 2016-04-13 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN105477627A (zh) * 2014-09-19 2016-04-13 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
CN105907840A (zh) * 2016-03-29 2016-08-31 苏州大学 单细胞水平检测mmp酶活性的方法
CN108451981A (zh) * 2018-04-21 2018-08-28 洛阳轩智生物科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
CN114377150A (zh) * 2021-12-29 2022-04-22 中山大学南昌研究院 一种mmp酶敏感胎盘微环境和肿瘤微环境靶向载体及其制备方法和应用
CN116549325A (zh) * 2022-01-27 2023-08-08 南京大学 一种组合物、其制备方法、制剂及应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2017038473A1 (ja) * 2015-08-28 2018-06-14 天野エンザイム株式会社 エンドトキシン低減サーモリシン
US10137179B2 (en) * 2016-05-18 2018-11-27 Hyalo Technologies, LLC Composition and method of preparation of protease microparticulate slow release preparation
US12569594B2 (en) 2018-12-20 2026-03-10 The Steadman Clinic And Steadman Philippon Research Institute Decellularized tendon matrix methods and uses thereof
CN119530138B (zh) * 2024-12-05 2026-01-30 中国肉类食品综合研究中心 一种用于工业化细胞解离的多酶制剂及其使用方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101524527A (zh) * 2008-03-04 2009-09-09 台湾尖端先进生技医药股份有限公司 作为体内造血刺激剂的tat-hoxb4h重组蛋白质及其医疗组成物
WO2010038610A1 (ja) * 2008-09-30 2010-04-08 オリエンタル酵母工業株式会社 新しい軟骨細胞増殖及び分化誘導剤
WO2011119829A1 (en) * 2010-03-24 2011-09-29 Lifenet Health Bmp-4 peptides & methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5770691A (en) * 1995-06-05 1998-06-23 Regents Of The University Of Minnesota Discriminatory substrates for MMP hydrolysis
ES2317657T3 (es) 1996-09-19 2009-04-16 The Regents Of The University Of Michigan Polimeros que contienen polisacaridos tales como alginatos o alginatos modificados.
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
WO1999055396A1 (en) 1998-04-27 1999-11-04 Surmodics, Inc. Bioactive agent release coating
US6376742B1 (en) 1999-02-17 2002-04-23 Richard J. Zdrahala In vivo tissue engineering with biodegradable polymers
WO2000051662A1 (en) 1999-03-04 2000-09-08 Tepha, Inc. Bioabsorbable, biocompatible polymers for tissue engineering
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
EP1611233B1 (en) * 2003-04-08 2016-01-06 Yeda Research And Development Co., Ltd. Stem cells having increased sensitivity to sdf-1 and methods of generating and using same
SE0302559D0 (sv) * 2003-09-25 2003-09-25 Astrazeneca Ab Method
JP2007508018A (ja) * 2003-10-08 2007-04-05 べト−ステム インコーポレイテッド 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット
CA2633980A1 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2007117451A2 (en) * 2006-03-31 2007-10-18 The Regents Of The University Of Michigan A pericellular collagenase directs the 3-dimensional development of white adipose tissue
MX2010003019A (es) * 2007-09-19 2010-04-30 Pluristem Ltd Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia.
JP5572291B2 (ja) * 2008-04-07 2014-08-13 独立行政法人国立長寿医療研究センター 歯髄及び／又は象牙質形成促進のための薬剤及びその利用
EP2608809B1 (en) * 2010-08-27 2019-05-22 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101524527A (zh) * 2008-03-04 2009-09-09 台湾尖端先进生技医药股份有限公司 作为体内造血刺激剂的tat-hoxb4h重组蛋白质及其医疗组成物
WO2010038610A1 (ja) * 2008-09-30 2010-04-08 オリエンタル酵母工業株式会社 新しい軟骨細胞増殖及び分化誘導剤
WO2011119829A1 (en) * 2010-03-24 2011-09-29 Lifenet Health Bmp-4 peptides & methods of use

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
CN105412917B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗实体瘤的抗癌组合物及其用途
CN105477628A (zh) * 2014-09-19 2016-04-13 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN105477627A (zh) * 2014-09-19 2016-04-13 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
CN105412916B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
CN105412917A (zh) * 2014-09-19 2016-03-23 达森生物药业有限公司 治疗实体瘤的抗癌组合物及其用途
CN105412916A (zh) * 2014-09-19 2016-03-23 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN105907840A (zh) * 2016-03-29 2016-08-31 苏州大学 单细胞水平检测mmp酶活性的方法
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
CN108451981A (zh) * 2018-04-21 2018-08-28 洛阳轩智生物科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
CN114377150A (zh) * 2021-12-29 2022-04-22 中山大学南昌研究院 一种mmp酶敏感胎盘微环境和肿瘤微环境靶向载体及其制备方法和应用
CN114377150B (zh) * 2021-12-29 2023-10-13 中山大学南昌研究院 一种mmp酶敏感胎盘微环境和肿瘤微环境靶向载体及其制备方法和应用
CN116549325A (zh) * 2022-01-27 2023-08-08 南京大学 一种组合物、其制备方法、制剂及应用
CN116549325B (zh) * 2022-01-27 2025-07-29 南京大学 一种组合物、其制备方法、制剂及应用

Also Published As

Publication number Publication date
HK1221405A1 (zh) 2017-06-02
MX2015014053A (es) 2016-04-07
EP2981276A4 (en) 2017-03-22
AU2014248002A1 (en) 2015-11-19
JP2016520550A (ja) 2016-07-14
PH12015502306A1 (en) 2016-02-15
US20160053250A1 (en) 2016-02-25
RU2015147878A (ru) 2017-05-10
CR20150603A (es) 2016-04-04
SG11201508199QA (en) 2015-11-27
BR112015025390A2 (pt) 2017-08-29
EP2981276A2 (en) 2016-02-10
EP3290047A1 (en) 2018-03-07
WO2014165780A3 (en) 2014-12-18
CA2908739A1 (en) 2014-10-09
WO2014165780A2 (en) 2014-10-09
KR20160006694A (ko) 2016-01-19

Similar Documents

Publication Publication Date Title
CN105246500A (zh) 基质金属蛋白酶及其用途
El Fahime et al. In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity
Peçanha et al. Adipose-derived stem-cell treatment of skeletal muscle injury
US20220016110A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
Mead et al. Mesenchymal stem cell–derived small extracellular vesicles promote neuroprotection in rodent models of glaucoma
ES2684599T3 (es) Células adherentes de la placenta y uso de las mismas en el tratamiento de enfermedades
US10035834B2 (en) Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
JP6847664B2 (ja) Ｐ９７−ポリヌクレオチド複合体
BR112014020119A2 (pt) cultura de células-tronco mesenquimais
JP2020514305A (ja) ファーバー病を治療するための組成物及び方法
CN104955470A (zh) 利用了hmgb1片段的针对脊髄损伤的新型治疗方法
AU2018257071B2 (en) Peptide for inducing regeneration of tissue, and use thereof
EP3080246A2 (en) Compositions and methods for producing and administering brown adipocytes
WO2008148932A2 (en) Glycosylasparaginase for treatment of cancers or inflammatory diseases
El Moshy et al. Dental mesenchymal stem cell secretome: a cell-free therapeutic approach for tissue regeneration
Yin et al. Sustained released of microRNA-99b-3p abundant exosomes derived from adipose stem cell encapsulated with hydrogel microparticles (HMPs) for long-term osteoarthritis treatment
Mai Mouse bone marrow mesenchymal stem cell conditioned media and its derived exosomes in the treatment of Sjögren Syndrome-like disease in NOD mice
JP2025539084A (ja) 療法及び化粧品での使用のためのｓａｒｍ１作用薬
US11554158B2 (en) GPNMB compositions for treatment of skin wounds
US20220409698A1 (en) Composition for preventing or treating bone diseases comprising ccr2
NZ712630B2 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160113

WD01 Invention patent application deemed withdrawn after publication